(NASDAQ: KYNB) Kyntra Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 62.8%.
Kyntra Bio's earnings in 2026 is $183,192,000.On average, 5 Wall Street analysts forecast KYNB's earnings for 2026 to be -$34,690,060, with the lowest KYNB earnings forecast at -$39,562,371, and the highest KYNB earnings forecast at -$28,230,493. On average, 5 Wall Street analysts forecast KYNB's earnings for 2027 to be -$51,942,972, with the lowest KYNB earnings forecast at -$65,275,928, and the highest KYNB earnings forecast at -$39,412,148.
In 2028, KYNB is forecast to generate -$55,783,972 in earnings, with the lowest earnings forecast at -$77,537,485 and the highest earnings forecast at -$39,157,054.